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Abstract
In this review, first principles of positron emission tomography (PET) and single photon emission tomography (SPECT) are
discussed together with the relative strengths and weaknesses of both techniques. With both modalities it is possible to image and,
especially with PET, to measure regional tissue function, the particular function being interrogated depending on the actual tracer
being used. In the second part, the use of PET for neuroactivation studies is presented, illustrated with some key examples from
the literature using both perfusion and metabolism tracers. It is argued that the future of PET (and SPECT) neuroactivation
studies lies in the use of ligands. Possible approaches for performing ligand activation studies are discussed. © 2001 Elsevier
Science Ltd. All rights reserved.
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1. Introduction
At present, there is such an interest in neuroactiva-
tion studies that the term ‘functional imaging’ is often
equated with imaging the change in cerebral activity
following the presentation of a stimulus. This terminol-
ogy is probably, at least in part, due to the use of the
term ‘functional MRI’ (fMRI), which is used to distin-
guish it from ‘standard (structural) MRI’. However, for
two of the first techniques being able to image neuroac-
tivation tomographically, positron emission tomogra-
phy (PET) and single photon emission tomography
(SPECT), the use of the term ‘functional imaging’
solely for imaging flow and/or oxygenation changes is a
severe underestimation of their potential.
2. Positron emission tomography
PET is a tomographic imaging technique that allows
for accurate non-invasive in-vivo measurements of a
whole range of regional tissue functions in man. By
using different tracers, a multitude of physiological,
biochemical and pharmacokinetic parameters can be
measured. These include blood flow (perfusion), blood
volume (vascularity), oxygen utilisation, glucose
metabolism, pre- and post-synaptic receptor density
and affinity, neurotransmitter release, enzyme activity,
drug delivery and uptake, gene expression, etc. This
flexibility is a result of the fact that, in principle, nearly
all biological molecules can be labelled with positron
emitters such as carbon-11, nitrogen-13 and oxygen-15.
In addition, fluorine-18 is often used as a substitute of
hydrogen, which itself does not have an isotope suitable
for in-vivo use.
Apart from flexibility, PET is also characterised by
the ability to measure regional tissue tracer concentra-
tions with high degrees of accuracy and sensitivity. This
is based on the decay characteristics of positron emit-
ters. In tissue, the emission of a positron effectively
results in the simultaneous emission of two gamma
rays, each with a fixed energy of 511 keV. These two
annihilation photons are emitted in opposite directions
and are recorded by coincidence detection (i.e. simulta-
neous detection by two opposing detectors). These two
detectors define the line of response along which the
original annihilation took place. In other words, no
lead collimators are needed, thereby providing for opti-
mal sensitivity. As the total path length of both annihi-
lation photons together is also known, accurate
correction for tissue attenuation can be made using a
separate transmission scan.
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At present, PET represents the most selective and
sensitive (pico- to nano-molar range) method for mea-
suring molecular pathways and interactions in vivo
(Jones, 1996). Apart from its capacity to provide new
pathophysiological information on human disease, PET
is also important for the objective assessment of thera-
peutic efficacy and plays an ever increasing role in the
development of new drugs (Comar, 1995). Finally, in
those cases where it is difficult to determine whether a
change is due to progression of disease or to side-effects
of (chronic) medication, studies can be performed in
animal models of disease (Lammertsma et al., 1995).
3. Single photon emission tomography
SPECT differs from PET in that use is made of
gamma (single photon) emitters. This mode of detection
suffers from a number of disadvantages compared with
PET. Firstly, when a detector registers an event, there is
no information about the direction of the incoming
photon. To obtain positional information, use is made
of lead collimators. The collimator guarantees that only
photons from a predefined direction are accepted. The
lead collimator, however, results in a significant reduc-
tion in sensitivity. Further disadvantages are that both
sensitivity and spatial resolution are position-depen-
dent, that is they both decrease with increasing depth in
the body. As the path length through tissue is not
known, attenuation correction methods are more cum-
bersome than in PET. Finally, there are no single
photon emitting isotopes of the basic biological ele-
ments. Therefore, use is made of radionuclides, such as
Tc-99m, that are uncommon to the human body. The
fate of a tracer labelled with Tc-99m is not necessarily
the same as that of the native molecule, resulting in
potential interpretation problems. For example, there
are no satisfactory SPECT tracers for oxygen and
glucose metabolism (PET tracers can be used with
SPECT, but are not ideal due to the relatively high
energy of the annihilation photons).
Of course, SPECT also has some advantages. Firstly,
both equipment and radionuclides are readily available
in every nuclear medicine department. Radionuclides
usually have such a long half-life that they can be
bought commercially or can be eluted from a generator.
This is in contrast to PET where, due to the (very) short
half-life, radionuclides usually have to be produced
with an on-site cyclotron. In other words, SPECT is
much cheaper and, therefore, more widely available
than PET. A potentially important advantage of
SPECT receptor ligands is that, in general, specific
activities are much higher than those obtained with
carbon-11 ligands, which cannot be made carrier-free.
This can have consequences for low-density receptor
studies.
4. Neuroactivation studies
Functional brain imaging using radioactive inert
gases was pioneered by Lassen and coworkers in the
late 1950s. A few years later, a quantitative method for
the determination of regional cerebral blood flow was
described (Ingvar & Lassen, 1961). The method was
developed further to a tomographic technique using
SPECT and Xe-133. This method was subsequently
applied to initial investigations of the visual system in
normal controls (Henriksen, Paulson, & Lassen, 1981).
During the 1970s, PET emerged as an accurate
method for measuring regional cerebral blood flow and
metabolism. In the early 1980s, studies were performed
to demonstrate regional changes in both perfusion and
metabolism following a stimulus. Initially, analysis con-
sisted of subtracting a stimulus from a baseline image.
Later, sophisticated statistical packages (e.g. Statistical
Parametric Mapping) were developed (Friston et al.,
1995). These packages are now in regular use not only
for PET, but also for fMRI studies. The early studies
clearly demonstrated two important issues. Firstly, the
change in perfusion was associated with a similar
change in glucose metabolism, but there was an uncou-
pling with oxygen utilisation, which increased to a
much smaller extent (Fox & Raichle, 1986). Even now,
the mechanism of this uncoupling is a matter of debate.
Secondly, it was realised early on that control of the
stimulus was of vital importance for interpreting sig-
nals. A classical example was the difference in activa-
tion seen in normal controls and professional musicians
when listening to a piece of music (Mazziotta, Phelps,
Carson, & Kuhl, 1982).
Measurement of glucose metabolism using 18FDG
can be useful in assessing whether a certain treatment
has had any effect on global and regional metabolism.
It can also be used for comparing patients with normal
controls and for comparing different conditions in the
same subject as images with a high statistical quality
can be acquired. The relatively long half-life of fluorine-
18 (2 h) precludes repeat measurements in one scan-
ning session and results in a somewhat higher radiation
burden to the subject. Similar drawbacks apply to
studies with SPECT flow tracers. Nevertheless,
metabolic studies using 18FDG have significantly con-
tributed to the development of neuroactivation studies
in PET. Mapping of visual cortex metabolism following
visual stimulation was one of the first studies to be
reported in this new field of research (Phelps, Kuhl, &
Mazziotta, 1981; see Fig. 1).
The method of choice for repeat measurements in the
same subject is the use of H215O due to its short half-life
of 2 min. Initially, studies were performed in a quanti-
tative manner, i.e. regional cerebral blood flow (CBF)
was measured on a pixel-by-pixel level. Quantification
of perfusion, however, requires measurement of the
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input function (i.e. arterial cannulation; Lammertsma et
al., 1990), which is cumbersome, especially in normal
controls. A detailed knowledge of the tracer kinetics of
H215O indicated that studies could also be performed on
a qualitative basis, as there was a predictable relation-
ship between uptake of H215O and actual perfusion. It
should be noted, however, that ‘qualitative’ activation
studies require reproducible tracer injections (i.e. tim-
ing, duration, volume), preferably using an infusion
pump. In addition, similar to most other ‘functional
imaging’ techniques, it is not possible to detect any
global changes with this qualitative implementation. If
there is any suspicion of global changes, then a full
quantitative study is recommended.
With regard to the visual system, the first activation
study using H215O was reported in 1984. In this study, it
Fig. 2. Results of one of the first studies targeting specialised areas of
the visual cortex. In this study, H2
15O was used to measure regional
cerebral blood flow. The original legend was as follows: Parametric
and statistical scans at the level of striate and inferior occipital
cortices. (a) Parametric image of regional cerebral blood flow (rCBF)
during colour activation. The level of striate cortex is 1.2 cm above
the AC–PC line and that of the inferior occipital cortex 1.7 cm below
it. (b) Map of perturbation (variance). This was calculated from the
pixel-by-pixel grey value variance across all six scans divided by the
difference in grey values between the two rest scans (a reflection of
noise). To reduce noise, each scan was smoothed using a low-pass
filter of side length 5 pixels (i.e. 10.25 mm). (c) t-statistic map showing
the significance of any difference between colour and grey activated
scans. In order to remove variance due to changes in global blood
flow, the original scans have been normalised to a total brain blood
flow of 50 ml/100 ml/min. As the study was designed to look for an
area maximally responsive to colour but not to grey, a one-tailed
t-test was used. (d) Map of the covariance of grey values across all six
scans with the grey values of a reference pixel located in the striate
cortex. In all scans, white and red represent the greatest activity/sig-
nificance/covariance, and blue the least (reproduced with permission
from Lueck et al., 1989).
Fig. 1. Results of one of the first studies on regional activation of
cerebral activity following a visual stimulus. In this study, 18FDG was
used to measure regional cerebral glucose metabolism. The original
legend was as follows: (A) Sketches from actual brain slices at
approximately the level of the cross-sectional tomographic images
(4.4, 3.6, and 2.8 cm above the orbito-meatal plane). The blackened
areas at the posterior of the brain indicate the approximate location
of the primary (PVC) and associative (AVC) visual cortices. (B)
When the eyes are closed and patched, the tissue metabolic rate is
relatively low. (C) Stimulation by white light. The increasing glucose
metabolic rate appears as increasing shades of grey, with black being
the highest. Note the higher metabolic rate of the PVC and AVC
(arrows) when the subject is being visually stimulated. The border
zone between the posterior parietal cortex and the Broadmann area
19 of the AVC is also apparent when its metabolic rate is decreased
in the unstimulated state. (D) Metabolic response of the visual cortex
to the viewing of a complex visual scene (reproduced with permission
from Phelps et al., 1981).
was demonstrated that the increase in regional cerebral
blood flow within the visual cortex depended on the
rate of the visual stimulus given (Fox & Raichle, 1984).
It took some time before studies were reported in which
specialised areas of the visual cortex were targeted
directly by appropriate stimulus design, the first one
localising the human colour area (Lueck et al., 1989;
see Fig. 2). Since then, numerous studies have been
published, interrogating the visual system in detail (see,
for example, Watson, 2000 for a review).
In recent years, there has been a shift from PET to
fMRI activation studies. This is, at least in part, due to
the need to administer radioactivity in PET. Although
studies should, whenever possible, be performed with
fMRI, there remains a place for PET, namely in those
instances where a stimulus cannot easily be repeated
such as in some psychiatric conditions.
The future of PET activation studies, however, lies in
ligands. Ligand studies usually require approximately 1
h (Cunningham & Lammertsma, 1995), and it is
difficult to repeat measurements within the same ses-
sion. One possibility is to perform two separate studies
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Fig. 3. Parametric images of a human [11C]raclopride study through
a transaxial plane at the level of the striatum. The left image
represents the parameter R1, which is the ratio of local (i.e. pixel)
delivery of tracer and delivery to the reference tissue (in this case,
cerebellum). The right image represents binding potential BP, which
is related to the density of available receptors and the affinity of
binding of the ligand to the receptor. Raclopride is an antagonist of
the D2 receptor, and the right image clearly shows a high concentra-
tion of D2 receptors in the striatum. It should be noted that both
images are parametric images, each one being a single image repre-
senting the magnitude of a (different) functional entity on a pixel-by-
pixel level. The images were generated from a dynamic data
acquisition sequence (i.e. multiple scans over time) by applying a
tracer kinetic model to each pixel (reproduced with permission from
Gunn et al., 1997).
Fig. 5. Region of interest data from basal ganglia () and cerebellum
() single bolus plus infusion administration of [11C]raclopride. The
priming bolus is used to achieve a steady-state [11C]raclopride level in
tissue more rapidly. At 40 min, equilibrium has been reached, and the
concentration is much higher in the receptor-rich basal ganglia com-
pared with the receptor free cerebellum. At 40 min, 0.4 mg/kg of
amphetamine was administered intravenously, producing displace-
ment of raclopride (from the receptors, i.e. from the basal ganglia,
but not from the cerebellum) due to competition with increased
dopamine released in response to the amphetamine challenge. The
magnitude of the activation can now be estimated from the change in
basal ganglia-to-cerebellum ratio (reproduced with permission from
Carson et al., 1997).
Fig. 4. Results of one of the first receptor activation studies. In this
study, eight volunteers underwent two [11C]raclopride studies, one
under baseline conditions and one whilst playing a video game. The
volunteers received a reward for each game level achieved. Illustrated
are those regions of the brain in which there was a statistically
significant correlation between reduced [11C]raclopride BP and task
performance. This correlation was found to be more pronounced in
the ventral striatum. In the upper row, transverse and coronal glass
brain views are shown, highlighting voxels with a significant inverse
correlation of [11C]raclopride BP with the highest performance level
reached. In the bottom row, results of a statistical parametric map-
ping (SPM) analysis of the data are superimposed on representative
transaxial MRI brain slices. Note, that this study made use of the
method presented in the previous figure (figure kindly provided by Dr
Grasby, MRC Cyclotron Unit, Hammersmith Hospital, London).
under different conditions. As it is now possible to
generate functional images of receptor binding parame-
ters (Gunn, Lammertsma, Hume, & Cunningham,
1997; see Fig. 3), previously mentioned statistical pack-
ages can be applied to these images, thereby directly
detecting changes in binding on a pixel-by-pixel level
(Koepp et al., 1998; see Fig. 4). If studies need to be
performed in a single session, activation can only be
detected as a displacement of the expected tissue time-
activity curve, i.e. at a certain point in time, the ligand
is displaced from the receptor by competition from an
increased level of endogenous neurotransmitter that has
been released as a result of the activation. Although
initial attempts have been made (Friston et al., 1997),
analysis of these studies still requires a significant mod-
elling and statistical effort. A very promising technique
is the so-called bolus-plus-infusion method, in which
first a bolus of the ligand is given, followed by a
constant infusion (Carson et al., 1997). The purpose of
the bolus is to achieve steady-state tissue (i.e. receptor)
tracer concentrations as quickly as possible. Any release
of endogenous neurotransmitter will then result in a
different steady state, which can be assessed on a
pixel-by-pixel level. Presently, there is some experience
with carbon-11-labelled raclopride for assessing phar-
macologically induced dopamine release (see Fig. 5).
Clearly, much work still needs to be done with respect
to understanding observed changes (Laruelle, 2000) and
in assessing whether changes due to smaller (e.g. cogni-
tive) stimuli are large enough to be detected. If success-
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ful, however, results will be much more specific than
present PET or fMRI activation studies, which are
based on an indirect change in blood flow. Here,
SPECT could also play a more prominent role as the
steady-state technique is ideally tailored for the slower
SPECT scanners.
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